secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2026-09-28T12:10:41+00:00
Accession:  0001193125-26-403429
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Fate Therapeutics receives $15.0M CIRM CLIN2 grant for Phase 2 RECLAIM-LN trial of FT819
--------------------------------------------------------------------------------

- CIRM awarded Fate a $15.0 million CLIN2 grant on Sept 25, 2026 to support RECLAIM-LN, the Phase 2 potentially registrational trial of FT819.
- RECLAIM-LN (FT819-201; NCT07570862) plans to enroll approximately 53 refractory SLE patients with lupus nephritis; primary endpoint is complete renal response at Week 26.
- FT819 is an off-the-shelf iPSC-derived CAR T-cell therapy; Phase 1 data showed favorable safety and clinically meaningful SLEDAI-2K and UPCr improvements.
- FT819 holds FDA RMAT designation and was selected for the FDA's CMC Development and Readiness Pilot (CDRP) program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/0001193125-26-403429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/fate-20260925.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-403429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer